Semaglutide for Smoking Cessation in Patients With Diabetes: A Pilot Randomized Controlled Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adults (18 years or older) with type 2 diabetes
• Currently residing in Ontario
• Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months
• Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months.
• Have not used GLP-1 receptor agonists in the past six months.
• Able to provide informed consent
Locations
Other Locations
Canada
University of Ottawa Heart Institute
RECRUITING
Ottawa
Contact Information
Primary
Evyanne Quirouette
equirouette@ottawaheart.ca
613-696-7000
Backup
Nidhi Agrawal
NAgrawal@ottawaheart.ca
613-696-7000
Time Frame
Start Date: 2026-02-13
Estimated Completion Date: 2027-07
Participants
Target number of participants: 100
Treatments
Experimental: Intervention
Semaglutide + Combination NRT for up to 6 months
Active_comparator: Control
Combination NRT for up to 6 months
Related Therapeutic Areas
Sponsors
Leads: Ottawa Heart Institute Research Corporation